{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:43:40Z","timestamp":1790840620563,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metastatic metaplastic triple-negative breast cancer (mMpTNBC) is a rare, aggressive subtype with poor responsiveness to standard therapies. Sacituzumab govitecan (SG) is effective in metastatic TNBC (mTNBC), but data in mMpTNBC are limited to case reports. Patients and methods: This multinational, multicenter, retrospective case series was conducted within the CEBCC-102 real-world evidence project across 18 cancer centers. Female patients with histologically confirmed mMpTNBC treated with\u2009\u2265\u20092L SG outside of clinical trials in Poland, the Czech Republic and Slovakia between August 2021 and June 2025 were included. Clinical data, treatment outcomes, and adverse events (AEs) were collected from medical records and analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 303 patients with mTNBC treated with SG in second and later lines within the CEBCC-102 project, 13 women (4.3%) had mMpTNBC and were included in this analysis. Median age was 58\u00a0years. PD-L1 CPS\u2009\u2265\u200910 was found in 83% of tested cases. Overall response rate was 36.4%, clinical benefit rate 45.5%, median progression-free survival 3.2\u00a0months and median overall survival 8.9\u00a0months. Neutropenia (N\u2009=\u20099, 69%) was the most common AE; no febrile neutropenia or treatment discontinuations due to toxicity occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This first international real-world series of SG in mMpTNBC shows clinically relevant activity and manageable toxicity, addressing a critical evidence gap and supporting further prospective studies, particularly in PD-L1\u2013positive disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-025-07875-4","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:28:29Z","timestamp":1765279709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study"],"prefix":"10.1007","volume":"215","author":[{"given":"Justyna","family":"\u017bubrowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Pieni\u0105\u017cek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Polakiewicz-Gilowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslava","family":"Malej\u010d\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo\u0161","family":"Hol\u00e1nek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e1ta","family":"Soumarov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Konieczna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Danielewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Lisik-Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"\u0141acko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Kubeczko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Pacholczak-Madej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Biel\u010dikov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miros\u0142awa","family":"P\u00fcsk\u00fcll\u00fco\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"7875_CR1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28551","author":"B Thapa","year":"2022","unstructured":"Thapa B, Arobelidze S, Clark BA et al (2022) Metaplastic breast cancer: characteristics and survival outcomes. Cureus. https:\/\/doi.org\/10.7759\/cureus.28551","journal-title":"Cureus"},{"issue":"8","key":"7875_CR2","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.clbc.2023.04.004","volume":"23","author":"A Thomas","year":"2023","unstructured":"Thomas A, Douglas E, Reis-Filho JS, Gurcan MN, Wen HY (2023) Metaplastic breast cancer: current understanding and future directions. Clin Breast Cancer 23(8):775\u2013783. https:\/\/doi.org\/10.1016\/j.clbc.2023.04.004","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"7875_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3892\/ol.2024.14331","volume":"27","author":"M P\u00fcsk\u00fcll\u00fco\u011flu","year":"2024","unstructured":"P\u00fcsk\u00fcll\u00fco\u011flu M, Swiderska K, Konieczna A et al (2024) Clinical analysis of metaplastic breast carcinoma with distant metastases: a multi-centre experience. Oncol Lett 27(5):198. https:\/\/doi.org\/10.3892\/ol.2024.14331","journal-title":"Oncol Lett"},{"issue":"1","key":"7875_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13058-020-01353-z","volume":"22","author":"TP Reddy","year":"2020","unstructured":"Reddy TP, Rosato RR, Li X, Moulder S, Piwnica-Worms H, Chang JC (2020) A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. Breast Cancer Res 22(1):121. https:\/\/doi.org\/10.1186\/s13058-020-01353-z","journal-title":"Breast Cancer Res"},{"issue":"3","key":"7875_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10549-017-4367-5","volume":"165","author":"CM Leyrer","year":"2017","unstructured":"Leyrer CM, Berriochoa CA, Agrawal S et al (2017) Predictive factors on outcomes in metaplastic breast cancer. Breast Cancer Res Treat 165(3):499\u2013504. https:\/\/doi.org\/10.1007\/s10549-017-4367-5","journal-title":"Breast Cancer Res Treat"},{"key":"7875_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.572230","volume":"11","author":"T Lan","year":"2021","unstructured":"Lan T, Lu Y, Zheng R et al (2021) The role of adjuvant chemotherapy in metaplastic breast carcinoma: a competing risk analysis of the SEER database. Front Oncol 11:572230. https:\/\/doi.org\/10.3389\/fonc.2021.572230","journal-title":"Front Oncol"},{"key":"7875_CR7","unstructured":"Guidelines Detail. NCCN. (2025) https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419"},{"key":"7875_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103756","volume":"76","author":"F Cardoso","year":"2024","unstructured":"Cardoso F, Paluch-Shimon S, Schumacher-Wulf E et al (2024) 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast 76:103756. https:\/\/doi.org\/10.1016\/j.breast.2024.103756","journal-title":"Breast"},{"issue":"16","key":"7875_CR9","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM et al (2021) Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 384(16):1529\u20131541. https:\/\/doi.org\/10.1056\/NEJMoa2028485","journal-title":"N Engl J Med"},{"issue":"12","key":"7875_CR10","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41416-024-02685-9","volume":"130","author":"D Hanna","year":"2024","unstructured":"Hanna D, Merrick S, Ghose A et al (2024) Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. Br J Cancer 130(12):1916\u20131920. https:\/\/doi.org\/10.1038\/s41416-024-02685-9","journal-title":"Br J Cancer"},{"key":"7875_CR11","doi-asserted-by":"publisher","first-page":"1362641","DOI":"10.3389\/fonc.2024.1362641","volume":"14","author":"R Caputo","year":"2024","unstructured":"Caputo R, Buono G, Piezzo M et al (2024) Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis. Front Oncol 14:1362641. https:\/\/doi.org\/10.3389\/fonc.2024.1362641","journal-title":"Front Oncol"},{"key":"7875_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231200454","author":"M Reinisch","year":"2023","unstructured":"Reinisch M, Bruzas S, Spoenlein J et al (2023) Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany. Ther Adv Med Oncol. https:\/\/doi.org\/10.1177\/17588359231200454","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"7875_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40487-024-00307-1","volume":"12","author":"M P\u00fcsk\u00fcll\u00fco\u011flu","year":"2024","unstructured":"P\u00fcsk\u00fcll\u00fco\u011flu M, Pieni\u0105\u017cek M, Las-Jankowska M et al (2024) Sacituzumab Govitecan for second and subsequent line palliative treatment of patients with triple-negative breast cancer: a Polish real-world multicenter cohort study. Oncol Ther 12(4):787\u2013801. https:\/\/doi.org\/10.1007\/s40487-024-00307-1","journal-title":"Oncol Ther"},{"key":"7875_CR14","unstructured":"Maheswaran S, Dedeoglu AS, Niemierko A, et al. A retrospective analysis of metaplastic triple negative breast cancer response to sacituzumab govitecan and candidacy for targeted therapy."},{"key":"7875_CR15","unstructured":"Nogueira-Rodrigues A, Pereira DJ, Arenhardt MP, Giannecchini GV. (2025) Case Report on Complete Response to Treatment of Metastatic Metaplastic Breast Cancer with Sacituzumab Govitecan. Annals of Case Reports. Published online January 5, 2024. https:\/\/www.gavinpublishers.com\/article\/view\/case-report-on-complete-response-to-treatment-of-metastatic-metaplastic-breast-cancer-with-sacituzumab-govitecan"},{"key":"7875_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpccr.2023.100239","volume":"10","author":"S Dong","year":"2023","unstructured":"Dong S, Fang Y, Syed S (2023) A rare case of advanced metaplastic breast carcinoma with response to treatment with Sacituzumab govitecan. Current Probl in Cancer: Case Rep 10:100239. https:\/\/doi.org\/10.1016\/j.cpccr.2023.100239","journal-title":"Current Probl in Cancer: Case Rep"},{"key":"7875_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2020.151490","volume":"46","author":"MCA Balkenhol","year":"2020","unstructured":"Balkenhol MCA, Vreuls W, Wauters CAP, Mol SJJ, Van Der Laak JAWM, Bult P (2020) Histological subtypes in triple negative breast cancer are associated with specific information on survival. Ann Diagn Pathol 46:151490. https:\/\/doi.org\/10.1016\/j.anndiagpath.2020.151490","journal-title":"Ann Diagn Pathol"},{"key":"7875_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2024.105640","volume":"152","author":"C Grosse","year":"2024","unstructured":"Grosse C, Noack P, Grosse A et al (2024) Prognostic impact of histological subtyping in triple-negative breast cancer. Hum Pathol 152:105640. https:\/\/doi.org\/10.1016\/j.humpath.2024.105640","journal-title":"Hum Pathol"},{"issue":"6","key":"7875_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131409","volume":"10","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Lv F, Yang Y et al (2015) Clinicopathological features and prognosis of metaplastic breast carcinoma: experience of a major Chinese cancer center. PLoS ONE 10(6):e0131409. https:\/\/doi.org\/10.1371\/journal.pone.0131409","journal-title":"PLoS ONE"},{"issue":"11","key":"7875_CR20","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1038\/s41416-020-01065-3","volume":"123","author":"E Kalaw","year":"2020","unstructured":"Kalaw E, Lim M, Kutasovic JR et al (2020) Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1. Br J Cancer 123(11):1665\u20131672. https:\/\/doi.org\/10.1038\/s41416-020-01065-3","journal-title":"Br J Cancer"},{"issue":"2","key":"7875_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.60312","volume":"8","author":"K Demarest","year":"2025","unstructured":"Demarest K, Anantharajah A, Maxwell KN et al (2025) Pathogenic germline variants in patients with metaplastic breast cancer. JAMA Netw Open 8(2):e2460312. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.60312","journal-title":"JAMA Netw Open"},{"key":"7875_CR22","doi-asserted-by":"publisher","first-page":"S443","DOI":"10.1016\/j.annonc.2025.08.988","volume":"36","author":"M Pieniazek","year":"2025","unstructured":"Pieniazek M, Puskulluoglu M, Polakiewicz-Gilowska A et al (2025) 566p effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer: a real-world retrospective cohort study from central Europe. Ann Oncol 36:S443\u2013S444. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.988","journal-title":"Ann Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07875-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07875-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07875-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:38:45Z","timestamp":1767789525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07875-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7875"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07875-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Justyna \u017bubrowska received travel grants and lecture fees from MSD, Novartis, and AstraZeneca; and lecture fees from Pfizer, Swixx Biopharma, Gilead and Eli Lilly. Ma\u0142gorzata Pieni\u0105\u017cek received travel support and lecture fees from Pfizer and Novartis; lecture fees from Gilead; and participated in an advisory board for Novartis. Anna Polakiewicz-Gilowska received lecture honoraria and travel support from AstraZeneca, Roche, Novartis, Eli Lilly, Swixx Biopharma, Gilead, and Pfizer. Miro-slava Malej\u010d\u00edkov\u00e1 served as a consultant and expert advisor for Novartis, Amgen, Pfizer, Roche, and AstraZeneca; received honoraria from Novartis, Pfizer, Roche, Teva, and AstraZeneca; and partici-pated in clinical studies sponsored by Novartis, Roche, AstraZeneca, and Pfizer. Milo\u0161 Hol\u00e1nek re-ceived travel and conference support from MSD, Gilead, Eli Lilly, and AstraZeneca; received lec-ture and speaker\u2019s fees from Novartis, Gilead, Eli Lilly, and Teva; and served on advisory boards for AstraZeneca, Eli Lilly, and Gilead. Ren\u00e1ta Soumarov\u00e1 received honoraria and support from BMS, AstraZeneca, Pfizer, Novartis, Eli Lilly, MSD, Gilead, Janssen, Astellas, Servier, Accord, and GSK, including advisory board participation. Aleksandra Konieczna received travel grants and lecture fees from Pfizer, Novartis, Eli Lilly, MSD, AstraZeneca, and Gilead; and advisory board honoraria from Novartis. Iwona Danielewicz declares no conflicts of interest. Maja Lisik-Habib received honoraria for lectures from MSD, AstraZeneca, Johnson & Johnson, Roche, BMS, Astellas, Merck, and GSK. Aleksandra \u0141acko received honoraria and support from AstraZeneca, Pfizer, Novartis, Eli Lilly, Roche, and Gilead Sciences, including advisory board participation. Marcin Kubeczko served on advisory boards for Novartis; received speaker\u2019s fees and conference support from Novartis, Roche, MSD, Pfizer, Eli Lilly, Teva, Amgen, Swixx Biopharma, AstraZeneca, and Gilead; and participated in clinical trials sponsored by Roche, MSD, Novartis, Seagen, and Gilead. Renata Pacholczak-Madej received travel grants from Accord and BMS; and lecture fees from AstraZeneca, BMS, MSD, GSK, Novartis, and Roche. Zuzana Biel\u010dikov\u00e1 received travel grants and lecture honoraria from AstraZeneca, MSD, Roche, Novartis, Eli Lilly, and Gilead. Miros\u0142awa P\u00fcsk\u00fcll\u00fco\u011flu received travel grants and lecture honoraria from AstraZeneca, Roche, Novartis, Eli Lilly, Janssen, Gilead, and Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"35"}}